» Articles » PMID: 7523697

Vaccines Prepared from Chimeras of Foot-and-mouth Disease Virus (FMDV) Induce Neutralizing Antibodies and Protective Immunity to Multiple Serotypes of FMDV

Overview
Journal J Virol
Date 1994 Nov 1
PMID 7523697
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

The G-H loop of VP1 (residues 132 to 159) of foot-and-mouth disease virus (FMDV) is a prominent feature on the virion surface and has an important role in vaccine efficacy, generation of antigenic variants, and cell binding. Using an infectious cDNA of FMDV, we have constructed serotype A viruses in which the G-H loop has been substituted with the homologous sequences from serotype O or C. These chimeric viruses replicated to high titer and displayed plaque morphologies similar to those of wild-type viruses, demonstrating that the functions provided by the loop can be readily exchanged between serotypes. Monoclonal antibody analyses showed that epitopes contained within the loop were transferred to the chimeras and that epitopes encoded by the type A backbone were maintained. Chemically inactivated vaccines prepared from chimeric viruses induced antibodies in guinea pigs that neutralized both type A and either type O or type C viruses. Swine inoculated with the A/C chimera vaccine also produced cross-reactive antibodies, were protected from challenge with the type A virus, and partially protected against challenge with type C. These studies emphasize the importance of epitopes outside of the G-H loop in protective immunity in swine, which is a natural host of FMDV.

Citing Articles

Defining correlates of protection for mammalian livestock vaccines against high-priority viral diseases.

Davis S, Jia F, Wright Q, Islam M, Bean A, Layton D Front Immunol. 2024; 15:1397780.

PMID: 39100679 PMC: 11294087. DOI: 10.3389/fimmu.2024.1397780.


The Parallel Presentation of Two Functional CTL Epitopes Derived from the O and Asia 1 Serotypes of Foot-and-Mouth Disease Virus and Swine SLA-2*HB01: Implications for Universal Vaccine Development.

Feng L, Gao Y, Sun M, Li Z, Zhang Q, Yang J Cells. 2022; 11(24).

PMID: 36552780 PMC: 9777387. DOI: 10.3390/cells11244017.


Efficacy of SAT2 Foot-and-Mouth Disease Vaccines Formulated with Montanide ISA 206B and Quil-A Saponin Adjuvants.

Rathogwa N, Scott K, Opperman P, Theron J, Maree F Vaccines (Basel). 2021; 9(9).

PMID: 34579233 PMC: 8473074. DOI: 10.3390/vaccines9090996.


A Novel Plasmid DNA-Based Foot and Mouth Disease Virus Minigenome for Intracytoplasmic mRNA Production.

Semkum P, Kaewborisuth C, Thangthamniyom N, Theerawatanasirikul S, Lekcharoensuk C, Hansoongnern P Viruses. 2021; 13(6).

PMID: 34205958 PMC: 8229761. DOI: 10.3390/v13061047.


Advances in the Diagnosis of Foot-and-Mouth Disease.

Wong C, Yong C, Ong H, Ho K, Tan W Front Vet Sci. 2020; 7:477.

PMID: 32974392 PMC: 7473413. DOI: 10.3389/fvets.2020.00477.


References
1.
Doel T, Gale C, do Amaral C, Mulcahy G, DiMarchi R . Heterotypic protection induced by synthetic peptides corresponding to three serotypes of foot-and-mouth disease virus. J Virol. 1990; 64(5):2260-4. PMC: 249387. DOI: 10.1128/JVI.64.5.2260-2264.1990. View

2.
Mateu M, Martinez M, Capucci L, Andreu D, Giralt E, Sobrino F . A single amino acid substitution affects multiple overlapping epitopes in the major antigenic site of foot-and-mouth disease virus of serotype C. J Gen Virol. 1990; 71 ( Pt 3):629-37. DOI: 10.1099/0022-1317-71-3-629. View

3.
Parry N, Fox G, Rowlands D, Brown F, Fry E, Acharya R . Structural and serological evidence for a novel mechanism of antigenic variation in foot-and-mouth disease virus. Nature. 1990; 347(6293):569-72. DOI: 10.1038/347569a0. View

4.
Kitson J, McCahon D, Belsham G . Sequence analysis of monoclonal antibody resistant mutants of type O foot and mouth disease virus: evidence for the involvement of the three surface exposed capsid proteins in four antigenic sites. Virology. 1990; 179(1):26-34. DOI: 10.1016/0042-6822(90)90269-w. View

5.
Minor P, Ferguson M, Katrak K, Wood D, John A, Howlett J . Antigenic structure of chimeras of type 1 and type 3 poliovirus involving antigenic site 1. J Gen Virol. 1990; 71 ( Pt 11):2543-51. DOI: 10.1099/0022-1317-71-11-2543. View